Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) saw a large growth in short interest in December. As of December 31st, there was short interest totalling 1,133,185 shares, a growth of 18.0% from the December 14th total of 960,272 shares. Approximately 3.0% of the company’s shares are sold short. Based on an average daily trading volume, of 357,783 shares, the days-to-cover ratio is currently 3.2 days.
NYSEAMERICAN RNN opened at $1.08 on Friday. Rexahn Pharmaceuticals has a one year low of $0.85 and a one year high of $2.70.
Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) last posted its earnings results on Monday, November 5th. The company reported ($0.17) EPS for the quarter, meeting analysts’ consensus estimates of ($0.17).
RNN has been the subject of a number of research analyst reports. HC Wainwright set a $20.00 price objective on shares of Rexahn Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, September 25th. B. Riley set a $8.00 price objective on shares of Rexahn Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, October 2nd. Ifs Securities upgraded shares of Rexahn Pharmaceuticals from an “outperform” rating to a “strong-buy” rating in a report on Thursday, October 4th. Zacks Investment Research lowered shares of Rexahn Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 16th. Finally, Brookline Capital Management reiterated a “buy” rating on shares of Rexahn Pharmaceuticals in a report on Tuesday, November 27th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $8.75.
Rexahn Pharmaceuticals Company Profile
Rexahn Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer.
See Also: Initial Public Offering (IPO)
Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.